Bank of America Maintains Buy Rating for Beam Therapeutics
Alec Stranahan from Bank of America Securities reaffirmed a 'Buy' rating for Beam Therapeutics (NASDAQ:BEAM) with a target price of $47, indicating over 33% upside potential. The analyst noted that while Prime Medicine won an arbitration case against Beam, it is unlikely to significantly impact the company as it only affects one asset in Prime's portfolio.